Collection of functional potassium channel regulatory proteins, immobilised in microtitre plate format, is said to be the first functional protein array to be made commercially available
Sense Proteomic has announced the first ion channel protein array for use by discovery biologists.
Sense's Kv subunit protein array is a collection of functional potassium channel regulatory proteins, immobilised in microtitre plate format for easy use with conventional laboratory equipment.
This is the first time that such a functional protein array has been made commercially available.
Kv subunit protein array contains key human and rat potassium channel beta-subunit proteins.
Interactions between the arrayed proteins and other potassium channel and cellular components are recognised as potential sites for therapeutic intervention in conditions such as cardiac arrhythmia and epilepsy.
The channel subunits can be interrogated to identify interacting protein pathways and, importantly, they provide a cell-free method for screening new chemical entities for effects on channel-protein interactions and their potential to modulate potassium channel function.
"Kv subunit protein array provides a rapid, in vitro screening system for studying protein-protein and protein-ligand interactions in the ion channels field", said Rhian Hayward, product manager for Sense Proteomic.
"Sense Proteomic is delighted to bring another high quality drug discovery tool to the protein array arena." Roland Kozlowski, CEO of Sense Proteomic, commented: "This specifically targeted product exemplifies Sense Proteomic's strength and capability in the production of functional protein arrays and demonstrates our lead position in this sector.
With a full pipeline of protein array products, we are in a very strong position to capitalise on the emerging proteomics market, through our portfolio of high quality functional proteomics solutions for the biopharmaceutical industry." Kv subunit protein array follows Sense Proteomic's first commercially available protein microarray, Expressarray p53, which is designed for the cancer research market and launched in January 2002.
